Eli Lilly and Company's impressive Q4 earnings driven by tirzepatide's success, diverse portfolio, and promising pipeline.

Ozempic and other glucagon-like peptide-1 (GLP-1) agonists are a transformative new class of medicines for the treatment of ...

Recent research suggests that a new approach could help even patients with advanced forms of fatty liver disease.

PATIENTS taking blockbuster diabetes and weight loss drugs are waking up with vision loss, researchers warn. Some reported ...

Big pharma’s pushing for PBS funding, and it’s kickstarting a shift to healthier snacks, smaller portions, and more ...

It should be used with a reduced-calorie diet and increased physical ... Those at risk include people living with type 2 diabetes or high blood pr Eli Lilly and Company (NYSE: LLY) today announced ...

The remarkable efficacy of new diabetes and weight loss medicines like Ozempic and Mounjaro have been one of the biggest health stories of recent years. Despite rising rates of diabetes and obesity, ...

The potential market for the drugs is massive — more than 40 percent of adults in the U.S. are obese — and has seen explosive ...

It is to be used together with a reduced-calorie diet and ... sector. Eli Lilly has revised its revenue forecast for 2024 after seeing weaker-than-expected growth for its diabetes and obesity ...

The FDA approved Steglatro (ertugliflozin) as a monotherapy in conjunction with diet ... is Eli Lilly/Boehringer’s Jardiance, which has broken new ground by being the first diabetes drug ...

The results were consistent with the preliminary results Eli Lilly shared in January, which disappointed investors.

Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the ...